

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

# **BMJ Open**

# The process of pain management in people with dementia living in nursing homes: a scoping review protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-063230
Article Type:	Protocol
Date Submitted by the Author:	25-Mar-2022
Complete List of Authors:	Overen, Caroline; Lovisenberg Diaconal University College Larsson, Maria; Karlstad University Hillestad, Adelheid ; Lovisenberg Diaconal University College Eriksen, Siren; Lovisenberg Diaconal University College; Norwegian National Centre for Ageing and Health
Keywords:	Dementia < NEUROLOGY, Pain management < ANAESTHETICS, PALLIATIVE CARE

# SCHOLARONE<sup>™</sup> Manuscripts

# Title: The process of pain management in people with

# dementia living in nursing homes: a scoping review

See tere

protocol

Authors:

Caroline Kreppen Overen, RN, MSc, PhD student, Lovisenberg Diaconal University College,

Oslo, Norway

Maria Larsson, RN, MSc, PhD, Professor, Faculty of Health, Science and Technology,

Department of Health Sciences, Karlstad University, Sweden

Adelheid Hummelvoll Hillestad, RN, MSc, PhD, Associate Professor, Lovisenberg Diaconal

University College, Oslo, Norway

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Siren Eriksen, RN, MSc, PhD, Professor, Lovisenberg Diaconal University College, Oslo, Norway; The Norwegian National Centre for Ageing and Health, Tønsberg, Norway

Corresponding author: Caroline Kreppen Overen, Lovisenberggata 15B, 0456 Oslo, Norway;

E-mail: Caroline.Kreppen.Overen@ldh.no; Telephone: + 47 93247819

Word count: 2068

#### ABSTRACT

L Ventia is d Introduction: The prevalence of dementia is dramatically increasing. Pain is a common symptom in people with dementia; untreated, it reduces quality of life and causes suffering. Since pain is a subjective experience, self-reporting is the gold standard of assessment methods. Healthcare professionals are advised to help people with dementia communicate about their pain, which can be challenging due to reduced cognitive function. The proposed scoping review is the first step in the development of a systematic pain management model for people with dementia living in nursing homes. It aims to identify, categorize, and summarize knowledge on how pain management processes in this population are described in the literature, focusing on how healthcare professionals can integrate self-reporting in the recognition, assessment, and evaluation of pain in this context.

#### **BMJ** Open

Methods and analysis: The scoping review will be conducted following the six-stage framework developed by Arksey and O'Malley and advanced by Levac et al.: (1) identify research question, (2) identify relevant studies, (3) select studies, (4) chart data, (5) collate, summarize, and report results, and (6) consult practitioners and consumers. Systematic searches in CINAHL, Embase, Medline, and PsycInfo will be conducted. The protocol follows the PRISMA-P and PRISMA-ScR checklists, and the scoping review will adhere to the PRISMA-ScR checklist. The review will include research that concerns the management of pain in people with dementia living in nursing homes. Studies will be assessed for quality and ethical standards. The summarizing and reporting of findings will follow Bradbury-Jones et al.'s PAGER framework. The research questions and results will be presented to and discussed in a reference group comprising nursing home residents, relatives, healthcare professionals, and nursing home managers.

**Ethics and disseminations:** The scoping review aims to collect and summarize data from available publications and does not require ethical approval. The final manuscript will be submitted to a peer-reviewed, open-access journal.

Registration in open science framework: https://osf.io/8kaf5/

**Keywords:** dementia, pain, pain assessment, pain management, nursing, healthcare professionals, nursing homes

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Strengths and limitations

The proposed scoping review is the first step in developing an intervention targeting systematic pain management for people with dementia living in nursing homes, adhering to the Medical Research Council's (MRC) framework for the development and evaluation of complex interventions. It aims to promote sustainable research and reduce research waste, by mapping the field early in the development process.
This review will use an established scoping review methodology and standardized

reporting guidelines.

- The included studies will be assessed for quality and ethical standards.
- The review may miss relevant literature, as it will not include grey literature nor studies not published in English/non-Nordic languages.



### INTRODUCTION

In 2016, dementia was the fifth leading cause of death worldwide<sup>1</sup> and the palliative perspective is important throughout the whole dementia trajectory.<sup>2</sup> As most people with dementia live their final days in a nursing home or similar,<sup>3,4</sup> healthcare professionals play an essential role in offering quality palliative care in this context. Moderate to severe stages of dementia have been described as an extended and intensive palliative care phase, often characterized by a loss of independence and autonomy, and reduction in physical and cognitive function.<sup>5</sup> The trajectory is often unpredictable and palliative care initiation should therefore reflect need, not prognosis.<sup>6</sup> A 5-round Delphi study resulted in 57 consensus-based recommendations for optimal palliative care in dementia, of which 8 are clinical.<sup>2</sup> One of these clinical domains is symptom relief, considered one of the main aspects of palliative care.<sup>7</sup>

#### **BMJ** Open

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Pain is a common symptom among people with dementia living in nursing homes.<sup>8-11</sup> In a recent study, van Dam et al. found that 43.3% of participants with dementia had clinically relevant pain scores.<sup>8</sup> Helvik et al. state that 35.5% of their participants had clinically relevant pain upon admittance to a nursing home.<sup>9</sup> A review conducted by Corbett et al. indicates that 50% of people with dementia regularly experience pain, and that the prevalence of pain in nursing home patients might be higher.<sup>10</sup> Pain in this patient group is often related to musculoskeletal, gastrointestinal, and cardiac conditions, genitourinary infections, and wounds.<sup>10</sup> Discomfort caused by pain in people with dementia can be expressed as behavioral and psychological symptoms (BPSD), such as agitation, apathy, restlessness, or wandering.<sup>2,12</sup> In Norway, the national clinical guidelines for dementia recommend that people with BPSD or other signs of discomfort should be assessed for pain as part of palliative care.<sup>13</sup>

Pain can be defined as *an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage.*<sup>14</sup> Pain is a symptom, which is a subjective experience, as opposed to signs, which can be observed.<sup>15,16</sup> These definitions implies that self-reported information is the most appropriate for assessing pain. This represents a challenge in the target population, who may have difficulty communicating their symptoms because of reduced cognitive function<sup>5,17</sup>—their pain may therefore go unrecognized and unmanaged.<sup>11</sup> One recommendation is the systematic use of standardized observational tools and skills to chart pain, which can compensate for patients' lack of verbal communication.<sup>2,13,18,19</sup> However, nurses often rely on experience-based knowledge when interpreting signs of pain, and less-experienced nurses may fail to recognize pain in people with dementia.<sup>20</sup> Moreover, Pautex et al. argue that the routine use of observational scales in

#### **BMJ** Open

severe dementia may not be justified, and that self-assessment can be reliably performed among this population.<sup>21</sup> Achterberg et al. highlight how self-reporting can also be adapted to individual capabilities during the course of dementia.<sup>11</sup> They recommend an initial use of simple numerical or verbal scales, and then the later use of "yes" or "no" questions; when cognitive and linguistic impairment reach a certain level, an observational tool can be added to the self-report to strengthen the validity of the pain assessment.

Pain management requires continuous mapping, assessment, and treatment evaluation.<sup>15</sup> When caring for people with dementia this is complex and challenging.<sup>22-24</sup> It relies on healthcare professionals' knowledge of individuals' normal level of functioning and communication methods<sup>22,25</sup>—and thus continuity of care. Healthcare professionals providing individualized care in nursing homes may be in a unique position to support and help people with dementia communicate their subjective experience of pain, if they have knowledge of and frequent contact with the residents.<sup>22,25</sup>

Healthcare professionals need tools to systematically assess and manage pain in people with dementia. The proposed scoping review is the first step in developing a care model to facilitate pain management in people with dementia living in nursing homes, and is rooted in the initial steps of the MRC framework for developing and evaluating complex interventions.<sup>26</sup> To promote sustainable research and reduce research waste, it is important to obtain a preliminary overview of the field of research.<sup>27</sup> To the best of our knowledge, no study has reviewed the literature on self-reporting in pain management processes in people with dementia living in nursing homes, and how healthcare professionals can integrate self-

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

reporting in recognizing, assessing, and evaluating pain in this group and context. The aim of this scoping review is therefore to identify, categorize, and summarize knowledge about these processes from the literature.

### METHODS AND ANALYSIS

The proposed scoping review will follow Arksey and O'Malley's six-stage methodological framework<sup>28</sup> and Levac et al.'s recommendations for each stage.<sup>29</sup> This will facilitate examination of the research concerning pain management in the target population, and the identification of knowledge gaps. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P)<sup>30</sup> and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklists<sup>31</sup> were used to prepare this protocol (supplementary files 1 and 2). PRISMA-ScR<sup>31</sup> will be used in the review.

#### Stage 1: Identify the research question(s)

Levac et al.<sup>29</sup> highlight that research questions as comprehensive and broad as those recommended by Arksey and O'Malley<sup>28</sup> may lack the direction, clarity, and focus needed to inform later steps in the research process. The concept and target population have therefore been defined to clarify the scoping review's focus and establish an effective search strategy, combined with a clear objective.<sup>29</sup> A Population, Concept, Context (PCC) framework has informed the research questions (table 1), and will guide the database searches and eligibility criteria.

Criteria	Determinants
Population	People with dementia
Concept	Pain management processes
Context	Nursing home

The following preliminary research questions were developed:

- How do healthcare professionals recognize, assess, and evaluate pain in people with dementia living in nursing homes?
- How are the management processes of self-reported pain in the target group described?

In accordance with Arksey and O'Malley, these may be adjusted as the review progresses.

#### Stage 2: Identify relevant studies

The research questions and key concepts will inform the search strategy. The CINAHL,

Embase, MEDLINE, and PsycInfo databases will be searched to identify relevant studies. The databases have been selected to cover a comprehensive range of healthcare research. A search strategy will be developed for each database with the assistance of an experienced librarian; these strategies will include medical subject headings (MESH), and search terms and synonyms combined using Boolean operators. The reference lists of included studies will be manually searched. In line with Arksey and O'Malley, the search process will be iterative, and search terms may be adapted as the research team gains familiarity with the literature.<sup>28</sup> A pilot search will be conducted, where the first ~80 references will be reviewed; the search

strategy will be adjusted if needed. A preliminary search was conducted on 11/2/22 (supplementary file 3).

### Stage 3: Select studies

Following Arksey and O'Malley, the scoping review will identify all relevant literature regardless of study design, to obtain a broad picture of the existing research on the chosen topic.<sup>28</sup> Similarly, no time limit for publication will be specified. The inclusion and exclusion criteria are presented below (table 2)—these may be revised as the study progresses,<sup>28</sup> and any revised criteria will be applied to all citations. The selection process will be documented in a PRISMA-flowchart<sup>32</sup> (figure 1), including reasons for exclusion.<sup>30</sup> If the relevance of a study is unclear from the title and abstract, the full article will be reviewed. Traditionally, scoping reviews do not include secondary research, such as literature reviews. However, literature reviews will be included; as interventions targeting pain management in people with dementia may have been developed based on literature reviews, it would be inappropriate to exclude articles that could help answer the research questions.

### Table 2. Preliminary eligibility criteria guiding study selection

Eligibility criteria	Inclusion criteria	Exclusion criteria
Source	Peer-reviewed journals Published in English, Norwegian, Swedish, or Danish	Grey literature

Population	People with dementia (e.g.,	Mixed samples (e.g., mild cognitive
	patients, service users, or	impairment/cognitive impairment +
	residents)	dementia)
		Dementia in people with Downs
		Syndrome
		Cognitive impairment not caused by
		dementia
Context	Nursing home	
Concept	Literature that describes:	
	How healthcare	
	professionals (including	
	nurses, nurse assistants, and	
	doctors), recognize, assess,	
	and evaluate pain in the	
	population	
	Whether and/or how self-	
	reporting of pain is	•
	integrated in pain	0
	management processes in the	4
	population	-7
	How healthcare	0.
	professionals can support	2/
	people with dementia in self-	
	reporting of pain	
Study design	All study designs	Editorials, commentaries or letters,
		discussion papers, opinion papers and
		nonempirical studies

#### Page 12 of 28

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### **BMJ** Open

Study selection will begin with a review of the title and abstract. If these correspond to the research questions and aim, a full-text review will be conducted. The studies will be reviewed by at least two researchers; in line with Levac et al., the research team will meet to discuss study inclusion and exclusion decisions in the beginning, middle, and final stages of the abstract review process, and refine the search strategy as needed.<sup>29</sup> At least two reviewers will independently review full-text articles for inclusion; if disagreement arises, an additional reviewer will be consulted to determine final inclusion.

Levac et al. argue that identifying gaps in the existing literature without assessing the quality of the included studies may lead to false conclusions about the nature and extent of those gaps; they also assert that quality assessment of the included studies will increase the likelihood that findings will be useful for practice.<sup>29</sup> Study quality will be therefore be assessed using appropriate appraisal tools, e.g., the Critical Appraisal Skills Programme (CASP)<sup>33</sup> and Mixed Methods Appraisal Tool (MMAT).<sup>34</sup> An additional researcher will be included in the decision making if disagreement or uncertainty arise around the quality assessment.

#### Stage 4: Charting data

This stage involves "charting" key items of information obtained from the included studies by sorting material according to relevant issues and themes. In the proposed scoping review, this will be a mixture of general and specific information relating to study design, study population, and the assessment tool. The charting process is also considered an iterative process, which means that the researchers may continuously update the data-charting form. In

#### **BMJ** Open

line with Levac et al., two researchers will independently extract data from the first five studies using the data-charting form and determine together whether the approach is consistent with the research questions and aim.<sup>29</sup> A preliminary data-charting form has been developed based on Arksey and O'Malley's template (table 3).<sup>28</sup> Ethical mapping is included in the data-charting form, in response to Weingarten et al.'s emphasis on increasing ethical awareness in reviews.<sup>35</sup> Articles that do not adhere to ethical standards will be excluded.

#### Table 3. Data-charting form

Data-charting	g form
• Authoria	or, date and country
• Study	v title
• Aim,	objective, and/or research questions
• Ethic	al assessment (financial support, conflicts of interest,
inform	med consent, research committee approval, data
prote	ction)
• Study	v context
• Partic	cipant characteristics
• Samp	ling method
• Desig	gn and methods
• Relev	vant findings

### Stage 5: Collate, summarize, and report results

As Arksey and O'Malley point out, unlike systematic reviews, scoping reviews do not synthesize evidence but instead provide an overview of the reviewed material.<sup>28</sup> In this stage, an overview and summary of the extracted information will therefore be prepared and presented, following the PAGER framework,<sup>36</sup> which consists of five categories: patterns, advances, gaps, evidence for practice, and research recommendations. Throughout the

process, there will be regular meetings of the research group to discuss and agree on aspects of the analytical process and how the findings should best be presented.

#### Stage 6: Consult with reference group

This scoping review is the first step in developing a complex intervention aiming to facilitate pain management in people with dementia living in nursing homes. Correspondingly, a reference group will be formed, consisting of nursing home residents, relatives, healthcare professionals, and nursing home managers. Arksey and O'Malley recommend consulting with practitioners and consumers to validate findings and make the research more useful for practice.<sup>28</sup> The findings will therefore be presented to and discussed with the reference group. In addition, the research team is part of a larger group of researchers, with whom the findings will also be discussed.

#### Patient and public involvement

The proposed scoping review's research questions and aim will be presented to and discussed with the reference group, as will the findings. These latter will support the development of an intervention promoting systematic pain management for people with dementia living in nursing homes.

### ETHICS AND DISSEMINATION

r of primary ear t et al.,<sup>3</sup> As the scoping review will not involve the collection of primary empirical data, ethical approval is unecessary.<sup>37</sup> However, following Weingarten et al.,<sup>35</sup> who state that ethical assessments of included studies should be conducted, ethical considerations are included in the data-charting process. Studies that do not adhere to ethical standards will be excluded. Findings from the scoping review will be published in an open-access, peer-reviewed journal. The scoping review is an important step in developing a pain management model for people

with dementia living in nursing homes. Findings will enable the identification of existing models or interventions that may be further developed and tailored to the nursing home context, preventing research waste.<sup>27</sup>

#### ACKNOWLEDGEMENTS

We would like to thank Annelie Ekberg-Andersson and Linda Borg—Information Specialists at Karlstad University—for their contribution to the search strategy presented in this protocol.

#### AUTHORS' CONTRIBUTIONS

CKO was responsible for the preliminary study design, conceptualized the review approach, and led the writing of this protocol. ML, AH, and SE contributed to the protocol's development and approved the final version. SE led the supervision of the protocol's preparation.

#### FUNDING STATEMENT

This research received no grant from any funding agency in the public, commercial, or not-

for-profit sectors.

#### COMPETING INTERESTS STATEMENT

None declared

 References:

- Nichols E, Szoeke CE, Vollset SE, et al. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology* 2019;18(1):88-106.
- 2. van der Steen JT, Radbruch L, Hertogh CMPM, et al. White paper defining optimal palliative care in older people with dementia: A Delphi study and recommendations from the European Association for Palliative Care. *Palliat Med* 2014;28(3):197-209. doi: 10.1177/0269216313493685
- 3. Houttekier D, Cohen J, Bilsen J, et al. Place of death of older persons with dementia. A study in five European countries. *J Am Geriatr Soc* 2010;58(4):751-56.
- 4. Mitchell SL, Teno JM, Miller SC, et al. A national study of the location of death for older persons with dementia. *J Am Geriatr Soc* 2005;53(2):299-305.
- 5. Hanson E, Hellström A, Sandvide Å, et al. The extended palliative phase of dementia An integrative literature review. *Dementia (London, England)* 2019;18(1):108-34. doi: 10.1177/1471301216659797 [published Online First: 2016/07/28]
- 6. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care:
  2020 report of the Lancet Commission. *Lancet* 2020;396(10248):413-46. doi:
  10.1016/s0140-6736(20)30367-6 [published Online First: 2020/08/03]
- 7. Radbruch L, De Lima L, Knaul F, et al. Redefining palliative Care—A new consensusbased definition. *J Pain Symptom Manage* 2020;60(4):754-64.

 van Dam PH, Caljouw MA, Slettebø DD, et al. Quality of life and pain medication use in persons with advanced dementia living in long-term care facilities. *J Am Med Dir Assoc* 2019;20(11):1432-37.

- 9. Helvik A-S, Bergh S, Šaltytė Benth J, et al. Pain in nursing home residents with dementia and its association to quality of life. *Aging Ment Health* 2021:1-11.
- 10. Corbett A, Husebo B, Malcangio M, et al. Assessment and treatment of pain in people with dementia. *Nature Reviews Neurology* 2012;8(5):264-74.

11. Achterberg W, Lautenbacher S, Husebo B, et al. Pain in dementia. Pain reports 2020;5(1)

- 12. Tible OP, Riese F, Savaskan E, et al. Best practice in the management of behavioural and psychological symptoms of dementia. *Ther Adv Neurol Disord* 2017;10(8):297-309.
- 13. Helsedirektoratet. Nasjonal faglig retningslinje for demens Oslo: Helsedirektoratet; 2017. Updated 03.01.20. Available from:

https://www.helsedirektoratet.no/retningslinjer/demens#apiUrl accessed 18.02.22.

- 14. International Association for the Study of Pain. Pain terms and definitions 2011. Available from: https://www.iasp-pain.org/resources/terminology/#pain accessed 21.03 2022.
- 15. Dodd M, Janson S, Facione N, et al. Advancing the science of symptom management. J Adv Nurs 2001;33(5):668-76.
- 16. Lenz ER, Pugh LC, Milligan RA, et al. The Middle-Range Theory of Unpleasant Symptoms: An Update. *Advances in Nursing Science* 1997;19(3):14-27.
- 17. Ellis-Smith C, Evans CJ, Bone AE, et al. Measures to assess commonly experienced symptoms for people with dementia in long-term care settings: a systematic review.
   *BMC medicine* 2016;14(1):1-12.

#### **BMJ** Open

- Husebo B, Ostelo R, Strand LI. The MOBID-2 pain scale: Reliability and responsiveness to pain in patients with dementia. *European journal of pain* 2014;18(10):1419-30.
- 19. Torvik K, Kaasa S, Kirkevold Ø, et al. Validation of Doloplus-2 among nonverbal nursing home patients-an evaluation of Doloplus-2 in a clinical setting. *BMC Geriatr* 2010;10(1):1-9.
- 20. Dowding D, Lichtner V, Allcock N, et al. Using sense-making theory to aid understanding of the recognition, assessment and management of pain in patients with dementia in acute hospital settings. *Int J Nurs Stud* 2016;53:152-62.
- 21. Pautex S, Michon A, Guedira M, et al. Pain in severe dementia: Self-assessment or observational scales? *J Am Geriatr Soc* 2006;54(7):1040-45.
- 22. De Witt Jansen B, Brazil K, Passmore P, et al. Exploring healthcare assistants' role and experience in pain assessment and management for people with advanced dementia towards the end of life: a qualitative study. *BMC Palliat Care* 2017;16(1):1-11.
- 23. De Witt Jansen B, Brazil K, Passmore P, et al. Nurses' experiences of pain management for people with advanced dementia approaching the end of life: a qualitative study. *Journal of Clinical Nursing (John Wiley & Sons, Inc)* 2017;26(9-10):1234-44. doi: 10.1111/jocn.13442
- 24. De Witt Jansen B, Brazil K, Passmore P, et al. "A tool doesn't add anything". The importance of added value: Use of observational pain tools with patients with advanced dementia approaching the end of life-a qualitative study of physician and nurse experiences and perspectives. *International Journal of Geriatric Psychiatry* 2018;33(7). doi: 10.1002/gps.4931

- 25. Monroe TB, Parish A, Mion LC. Decision Factors Nurses Use to Assess Pain in Nursing Home Residents With Dementia. *Archives of Psychiatric Nursing* 2015;29(5):316-20. doi: 10.1016/j.apnu.2015.05.007
- 26. Skivington K, Matthews L, Simpson SA, et al. Framework for the development and evaluation of complex interventions: gap analysis, workshop and consultation-informed update. *Health Technol Assess* 2021
- 27. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. *The Lancet* 2009;374(9683):86-89.
- 28. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International journal of social research methodology* 2005;8(1):19-32.
- 29. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implementation science* 2010;5(1):1-9.
- 30. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic reviews* 2015;4(1):1-9.
- Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med* 2018;169(7):467-73.
- 32. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *International Journal of Surgery* 2021;88:105906.
- 33. CASP Checklist: CASP Critical appraisal skills programme 2018. Available from: https://casp-uk.b-cdn.net/wp-content/uploads/2018/01/CASP-Qualitative-Checklist-2018.pdf accessed 25.08.21.

3	
4	
2	
6	
5 6 7	
8	
9	
10	
10	
11	
12	
13	
14	
15	
15 16 17	
10	
17	
18	
19	
20	
21	
20 21 22 23 24 25 26 27 28 29	
22	
23	
24	
25	
26	
27	
27	
28	
29	
30	
31	
32	
22	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	

60


34. Hong QN, Fàbregues S, Bartlett G, et al. The Mixed M	ethods Appraisal Tool (MMAT)
version 2018 for information professionals and rese	archers. Education for Information
2018;34(4):285-91.	

- 35. Weingarten MA, Paul M, Leibovici L. Assessing ethics of trials in systematic reviews. *BMJ*2004;328(7446):1013-14.
- 36. Bradbury-Jones C, Aveyard H, Herber OR, et al. Scoping reviews: the PAGER framework for improving the quality of reporting. *International Journal of Social Research Methodology* 2021:1-14.
- 37. Helseforskningsloven. Lov om medisinsk og helsefaglig forskning: Helse- og

omsorgsdepartementet, 2008.

Figure legends:

Figure 1: Overview study selection process using PRISMA Flow Diagram.<sup>32</sup>



\*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).

\*\*If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

# **SUPPLEMENTARY FILE 1**

# PRISMA-P 2015 Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* **2015** 4:1

Section/topic	#	# Checklist item		tion d	Line
			Yes	No	number(s)
	INFO	ORMATION			
Title					
Identification	1a	Identify the report as a protocol of a systematic review			5-6
Update	1b	If the protocol is for an update of a previous systematic review, identify as such			
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract			61
Authors		4			
Contact	За	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author			12-25
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review			316-320
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments			
Support			J		
Sources	5а	Indicate sources of financial or other support for the review			320-322
Sponsor	5b	Provide name for the review funder and/or sponsor		$\square$	
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol		$\square$	
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known			105-165
Objectives	7	Provide an explicit statement of the question(s) the review will address with			186-193

ו ר
2
3
4
5
6
7
8
9
9 10
11
12
13
14
15
16
17
18
10
20
20 21
∠ I วว
19 20 21 22 23
∠3 24
24 25
25
26
27
28
29 30
31
32
33
35
34 35 36
37 38
38
39
39 40
41 42
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
50 59
<u> </u>

reference to participants, interventions, comparators, and outcomes (PICO) Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated			number(s)222-223197-203Supplementary file 3
comparators, and outcomes (PICO) Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated			197-203 Supplementary
<ul> <li>PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review</li> <li>Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage</li> <li>Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated</li> </ul>			197-203 Supplementary
<ul> <li>PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review</li> <li>Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage</li> <li>Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated</li> </ul>			197-203 Supplementary
sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated			Supplementary
used for at least one electronic database, including planned limits, such that it could be repeated			
Describe the mechanism(s) that will be			
Describe the mechanism(s) that will be			
used to manage records and data throughout the review			214-215
State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)			210-230
Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators			342-255
List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications			254-255
List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale			242-255
Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis			
	<ul> <li>Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators</li> <li>List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications</li> <li>List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale</li> <li>Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be</li> </ul>	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigatorsImage: Confirming List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplificationsImage: Confirming List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationaleImage: Confirming Confirming List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationaleImage: Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming Confirming C	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators       Image: Content of the image: Conten of the image: Content of the image: Content o

Section/topic #	#	# Checklist item	Information reported		Line
			Yes	No	number(s)
	15a	Describe criteria under which study data will be quantitatively synthesized			
Synthesis	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., <i>I</i> <sup>2</sup> , Kendall's tau)			
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)			
150	15d	If quantitative synthesis is not appropriate, describe the type of summary planned			256-563
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)			
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)			

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

# **SUPPLEMENTARY FILE 2**

# Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

**BMJ** Open

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			ON PAGE #
Title	1	Identify the report as a scoping review.	1
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	2
INTRODUCTION			
Rationale 3		Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	4-5
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	6
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	1
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	7-8
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	6-7
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Supplementary file 3
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	7-8
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	9
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	9
Critical appraisal of individual	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this	8

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
sources of evidence§		information was used in any data synthesis (if appropriate).	
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	9
RESULTS			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	Click here to enter text.
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	Click here to enter text.
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Click here to enter text.
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	Click here to enter text.
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	Click here to enter text.
DISCUSSION			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	Click here to enter text.
Limitations	20	Discuss the limitations of the scoping review process.	Click here to enter text.
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	Click here to enter text.
FUNDING			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	13

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

\* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).
‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to

the process of data extraction in a scoping review as data charting. § The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMAScR): Checklist and Explanation. Ann Intern Med. 2018;169:467–473. doi: 10.7326/M18-0850.

## **SUPPLEMENTARY FILE 3**

# MEDLINE, Search conducted 11.02.22

## Database:

Ovid MEDLINE(R) ALL <1946 to February 10, 2022>

#	Query	Results from 11 Feb 2022	
1	dementia/ or alzheimer disease/ or dementia, vascular/ or frontotemporal lobar degeneration/ or lewy body disease/	160,450	
2	Frontotemporal Dementia/ or Dementia, Multi-Infarct/	4,719	
3	Korsakoff Syndrome/	530	
4	Dementia.ab,ti.	121,195	
5	"Alzheimer*".ab,ti.	163,697	
6	Lewy body.ab,ti.	4,218	
7	korsakoff.ab,ti.	985	
8	1 or 2 or 3 or 4 or 5 or 6 or 7	265,108	
9	exp Pain/ or exp Pain Measurement/ or exp Pain Management/	471,353	
10	Pain.ab,ti.	694,136	
11	9 or 10	872,991	
12	"Care home*".af.	5,045 🧹	
13	Long term care.af.	46,819	
14	Residential care.af.	4,053	
15	"nurs* home*".af.	52,581	
	exp Residential Facilities/ or exp Nursing Homes/ or exp Homes for the Aged/ or exp Long-Term Care/	77,440	
17	"Home* for the aged".af.	15,709	
18	12 or 13 or 14 or 15 or 16 or 17	107,035	
19	8 and 11 and 18	750	

# **BMJ Open**

# The process of pain assessment in people with dementia living in nursing homes: a scoping review protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-063230.R1
Article Type:	Protocol
Date Submitted by the Author:	31-Aug-2022
Complete List of Authors:	Overen, Caroline; Karlstad University Faculty of Health Science and Technology; Lovisenberg Diaconal University College Larsson, Maria; Karlstad University Faculty of Health Science and Technology Hillestad, Adelheid ; Lovisenberg Diaconal University College Eriksen, Siren; Lovisenberg Diaconal University College; Norwegian National Centre for Ageing and Health
<b>Primary Subject Heading</b> :	Palliative care
Secondary Subject Heading:	Nursing, Palliative care
Keywords:	Dementia < NEUROLOGY, Pain management < ANAESTHETICS, PALLIATIVE CARE



1 2		
2 3		
4 5 6	1	Title page:
7 8 9	2	
10 11 12	3	
13 14 15	4	Title: The process of pain assessment in people with
16 17 18 19	5	dementia living in nursing homes: a scoping review
20 21 22 23 24	6	protocol
25 26	7	
27 28 29	8	
30 31 32	9	
33 34	10	Authors:
35 36 37	11	
38 39 40	12	Caroline Kreppen Overen, RN, MSc, PhD student, Lovisenberg Diaconal University College,
41 42	13	Oslo, Norway
43 44 45	14	1
46 47	15	Maria Larsson, RN, MSc, PhD, Professor, Faculty of Health, Science and Technology,
48 49 50	16	Department of Health Sciences, Karlstad University, Sweden
51 52	17	
53 54 55	18	Adelheid Hummelvoll Hillestad, RN, MSc, PhD, Associate Professor, Lovisenberg Diaconal
56 57	19	University College, Oslo, Norway
58 59 60	20	

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

3
4 5 7 8 9 10
6
7
, 8
0
10
10
11
12
13 14
14
15
16
17
18
19
13         14         15         16         17         18         19         20         21         22         23         24         25         26         27         28         29         30         31         32
21
22
23
24
25
26
27
27
20
29
30
31 32 33
32
33
34
34 35 36 37 38
36
37
38
39
40
41
42
43
43 44
44 45
46
47
48
49
50
51
52
53
54
55
56
57
58
58 59
60

21 Siren Eriksen, RN, MSc, PhD, Professor, Lovisenberg Diaconal University College, Oslo,

22 Norway; The Norwegian National Centre for Ageing and Health, Tønsberg, Norway

#### 23

1 2

> 24 Corresponding author: Caroline Kreppen Overen, Lovisenberggata 15B, 0456 Oslo, Norway;

- 25 E-mail: Caroline.Kreppen.Overen@ldh.no; Telephone: + 47 93247819
- Word count: 2492 27
- 28

29

26

- 30

37

### 31

#### 32 ABSTRACT

, in . Introduction: Pain is a common symptom in people with dementia; untreated, it reduces 33 34 quality of life and causes suffering. People with dementia living in nursing homes most often have dementia in moderate to severe stages. The cognitive impairment, including language-35 and communication difficulties challenges pain assessment. 36

38 Since pain is a subjective experience, self-reporting is the gold standard of assessment 39 methods. Healthcare professionals are advised to help people with dementia communicate 40 about their pain. The proposed scoping review is the first step in the development of a 41 systematic pain assessment model for people with dementia living in nursing homes. The 42 scoping review aims to identify, categorize, and summarize knowledge on how pain

#### **BMJ** Open

assessment processes in this population are described in the literature, with a special focus on self-reporting. 

Methods and analysis: The scoping review will be conducted following the six-stage framework developed by Arksey and O'Malley and advanced by Levac et al.: (1) identify research question, (2) identify relevant studies, (3) select studies, (4) chart data, (5) collate, summarize, and report results, and (6) consult practitioners and consumers. Systematic searches in CINAHL, Embase, Medline, and PsycInfo will be conducted. The protocol follows the PRISMA-P and PRISMA-ScR checklists, and the scoping review will adhere to the PRISMA-ScR checklist. The review will include research that concerns assessment of pain in people with dementia living in nursing homes. Studies will be evaluated for quality and ethical standards. The analysis process will follow Bradbury-Jones et al.'s PAGER framework. Patterns will be formed using thematic analysis. An overview of advances, gaps, evidence for practice, and research recommendations associated with each pattern will be prepared. The research questions and results will be presented to and discussed in a reference group comprising nursing home residents, relatives, healthcare professionals, and nursing home managers. **Ethics and disseminations:** The scoping review aims to collect and summarize data from available publications and does not require ethical approval. The final manuscript will be submitted to a peer-reviewed, open-access journal. Registration in open science framework: https://osf.io/8kaf5/ 

BMJ Open

1

2		
3	67	Keywords: dementia, pain, pain assessment, pain management, nursing, healthcare
4	07	<b>Keywords.</b> dementia, pain, pain assessment, pain management, narsing, neartheare
5	60	
6 7	68	professionals, nursing homes
8		
9	69	
10		
11	70	
12		
13		
14		Strengths and limitations
15		
16		- This review will use an established scoping review methodology and standardized
17 18		
19		reporting guidelines.
20		
21		- To minimize the risk of personal biases two reviewers will independently assess the
22		- To minimize the fisk of personal blases two reviewers will independently assess the
23		
24		studies for inclusion or exclusion; if disagreement arises, an additional reviewer will
25		
26 27		be consulted.
28		
29		- The included studies will be assessed for quality and ethical standards.
30		
31		- The review may miss relevant literature, as it will not include grey literature nor
32		
33		studies not published in English/non-Nordic languages.
34 35		studies not published in English/non-ivordie ranguages.
36	74	
37	71	
38	72	
39		
40	73	
41 42	74	
43		
44	75	
45	76	
46		
47	77	
48 49	78	
49 50		
51	79	
52	80	
53	81	
54		
55	82	
56 57	83	
57 58		
59	84	
60	85	
	55	

# INTRODUCTION

In 2016, dementia was the fifth leading cause of death worldwide<sup>1</sup> and the palliative perspective is important throughout the whole dementia trajectory.<sup>2</sup> As most people with dementia live their final days in a nursing home or similar,<sup>3,4</sup> healthcare professionals play an essential role in offering quality palliative care in this context. The prevalence of dementia in nursing home residents worldwide differ by location, nation, and region. <sup>5</sup> In Norway as many as 80% of nursing home residents have dementia, and the majority has dementia in moderate to severe stage. <sup>6</sup> Moderate to severe stages of dementia have been described as an extended and intensive palliative care phase, often characterized by a loss of independence and autonomy, and reduction in physical and cognitive function.<sup>7</sup> The trajectory is often unpredictable and palliative care initiation should therefore reflect need, not prognosis.<sup>8</sup> A 5-round Delphi study resulted in 57 consensus-based recommendations for optimal palliative care in dementia, of which 8 are clinical.<sup>2</sup> One of these clinical domains is symptom relief, considered one of the main aspects of palliative care.<sup>9</sup> 

#### **BMJ** Open

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40 41
41 42
42 43
43 44
45
46
40 47
48
49
50
51
52
53
54
55
56
57
58
59
60

1

118	
119	Pain is a common symptom among people with dementia living in nursing homes. <sup>10-13</sup> In a
120	recent study, van Dam et al. found that 43.3% of participants with dementia had clinically
121	relevant pain scores. <sup>10</sup> Helvik et al. state that 35.5% of their participants had clinically
122	relevant pain upon admittance to a nursing home. <sup>11</sup> A review conducted by Corbett et al.
123	indicates that 50% of people with dementia regularly experience pain, and that the prevalence
124	of pain in nursing home patients might be higher. <sup>12</sup> Pain in this patient group is often related
125	to musculoskeletal, gastrointestinal, and cardiac conditions, genitourinary infections, and
126	wounds. <sup>12</sup> Discomfort caused by pain in people with dementia can be expressed as behavioral
127	and psychological symptoms (BPSD), such as agitation, apathy, restlessness, or wandering. <sup>2,14</sup>
128	In Norway, the national clinical guidelines for dementia recommend that people with BPSD
129	or other signs of discomfort should be assessed for pain as part of palliative care. <sup>15</sup> Pain
130	assessment is frequently compromised by cognitive impairment <sup>16</sup> , including aspects of
131	language and communication difficulties <sup>17</sup> in nursing home population.
132	
133	Pain can be defined as an unpleasant sensory and emotional experience associated with, or
134	resembling that associated with, actual or potential tissue damage. <sup>18</sup> Pain is a symptom, which
135	is a subjective experience, as opposed to signs, which can be observed. <sup>19,20</sup> These definitions
136	implies that self-reported information is the most appropriate for assessing pain. This
137	represents a challenge in the target population, who may have difficulty communicating their

symptoms because of reduced cognitive function<sup>7 21</sup>—their pain may therefore go

 $\frac{6}{7}$  139 unrecognized and unmanaged.<sup>13</sup> One recommendation is the systematic use of standardized

observational tools and skills to chart pain, which can compensate for patients' lack of verbal

#### **BMJ** Open

communication.<sup>2,15,22,23</sup> However, nurses often rely on experience-based knowledge when interpreting signs of pain, and less-experienced nurses may fail to recognize pain in people with dementia.<sup>24</sup> Moreover, Pautex et al. argue that the routine use of observational scales in severe dementia may not be justified, and that self-assessment can be reliably performed among this population.<sup>25</sup> Achterberg et al. highlight how self-reporting can also be adapted to individual capabilities during the course of dementia.<sup>13</sup> They recommend an initial use of simple numerical or verbal scales, and then the later use of "yes" or "no" questions; when cognitive and linguistic impairment reach a certain level, an observational tool can be added to the self-report to strengthen the validity of the pain assessment. Pain management requires continuous mapping, assessment, and treatment evaluation.<sup>19</sup> When caring for people with dementia this is complex and challenging.<sup>26-28</sup> It relies on healthcare professionals' knowledge of individuals' normal level of functioning and communication methods<sup>26,29</sup> Healthcare professionals providing individualized care in nursing homes may be in a unique position to support and help people with dementia communicate their subjective experience of pain, if they have knowledge of and frequent contact with the residents.26,29 Healthcare professionals in nursing homes need tools to systematically manage pain in people with dementia, which consider individual variation in pain expressions and ability to self-report. The proposed scoping review is the first step in developing a care model for systematic pain assessment in people with dementia living in nursing homes, which also includes how healthcare professionals recognize pain and evaluate initiated measures. The development of 

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### **BMJ** Open

this model is rooted in the initial steps of the MRC framework for developing and evaluating complex interventions.<sup>30</sup> To promote sustainable research and reduce research waste, it is important to obtain a preliminary overview of the field of research.<sup>31</sup> To the best of our knowledge, no study has reviewed the literature on self-reporting in pain assessment processes in people with dementia living in nursing homes, and how healthcare professionals can integrate self-reporting in recognizing, assessing, and evaluating pain in this group and context. The aim of this scoping review is therefore to identify, categorize, and summarize knowledge about these processes from the literature. METHODS AND ANALYSIS The proposed scoping review will follow Arksey and O'Malley's six-stage methodological framework<sup>32</sup> and Levac et al.'s recommendations for each stage.<sup>33</sup> This will facilitate examination of the research concerning pain assessment in the target population, and the identification of knowledge gaps. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P)<sup>34</sup> and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklists<sup>35</sup> were used to prepare this protocol (supplementary files 1 and 2). PRISMA-ScR<sup>35</sup> will be used in the review. The scoping review will be carried out in the period March 2022 - September 2023. Stage 1: Identify the research question(s) Levac et al.<sup>33</sup> highlight that research questions as comprehensive and broad as those recommended by Arksey and O'Malley<sup>32</sup> may lack the direction, clarity, and focus needed to inform later steps in the research process. The concept and target population have therefore 

Page 9 of 29

1 2			
3 4	187	been defined to	clarify the scoping review's focus and establish an effective search strategy,
5 6 7	188	combined with a	a clear objective. <sup>33</sup> A Population, Concept, Context (PCC) framework has
8 9	189	informed the res	search questions (table 1), and will guide the database searches and eligibility
10 11 12	190	criteria.	
13 14	191		
15 16	192	Table 1. PCC fra	amework informing research questions and search strategy
17 18	193		
19 20		Criteria	Determinants
21 22		Population	People with dementia
23		1.01.000	
24 25		Concept	Pain assessment processes
26 27		Context	Nursing home
28 29 30	194		
31 32	195	The following p	reliminary research questions were developed:
33 34 35	196	- How do	healthcare professionals recognize and assess pain in people with dementia
36 37	197	living in	nursing homes?
38 39 40	198	- How are	the assessment processes of self-reported pain in the target group described?
41 42 43	199	In accordance w	ith Arksey and O'Malley, these may be adjusted as the review progresses.
44 45	200		
46 47 48	201		
48 49 50	202		
51 52 53	203	Stage 2: Identify	relevant studies
55 55	204	The research que	estions and key concepts will inform the search strategy. The CINAHL,
56 57 58	205	Embase, MEDL	INE, and PsycInfo databases will be searched to identify relevant studies. The
59 60	206	databases have b	been selected to cover a comprehensive range of healthcare research. A search

#### **BMJ** Open

> strategy will be developed for each database with the assistance of an experienced librarian; these strategies will include medical subject headings (MESH), and search terms and synonyms combined using Boolean operators. The search strategy will consist of three main blocks informed by the PCC framework (table 1): People with dementia (population), pain assessment processes (concept of interest) and nursing home (context). The different search terms in each block will be combined with OR, and the blocks will be combined with AND. The reference lists of included studies will be manually searched. In line with Arksey and O'Malley, the search process will be iterative, and search terms may be adapted as the research team gains familiarity with the literature.<sup>32</sup> A pilot search will be conducted, where the first ~80 references will be reviewed; the search strategy will be adjusted if needed. A preliminary search was conducted on 11/2/22 (supplementary file 3).

#### 219 Stage 3: Select studies

Following Arksey and O'Malley, the scoping review will identify all relevant literature regardless of study design, to obtain a broad picture of the existing research on the chosen topic.<sup>32</sup> Similarly, no time limit for publication will be specified. The inclusion and exclusion criteria are presented below (table 2)—these may be revised as the study progresses,<sup>32</sup> and any revised criteria will be applied to all citations. The selection process will be documented in a PRISMA-flowchart <sup>36</sup> (figure 1), including reasons for exclusion.<sup>34</sup> Duplicates will be removed using Endnote and the duplicates not detected by Endnote will be removed manually as the abstracts are reviewed. If the relevance of a study is unclear from the title and abstract, the full article will be reviewed. Traditionally, scoping reviews do not include secondary research, such as literature reviews. However, literature reviews will be included; as 

230	interventions ta	rgeting pain management in people w	vith dementia may have been developed
231	based on literature reviews, it would be inappropriate to exclude articles that could help		
232	answer the research questions.		
233			
234			
235			
236			
222	Table 2 Dealier	in anti-aliaikiliter anitania anti-dina atu-du	alaction
237		inary eligibility criteria guiding study	selection
	Eligibility	Inclusion criteria	Exclusion criteria
	criteria	°C,	
	Source	Peer-reviewed journals	Grey literature
		Published in English,	
		Norwegian, Swedish, or Danish	
	Population	People with dementia (e.g.,	Mixed samples (e.g., mild cognitive
		patients, service users, or residents)	impairment/cognitive impairment + dementia)
		Testuents)	Dementia in people with Downs
			Syndrome
			Cognitive impairment not caused by
			dementia
	Context	Nursing home	
	Concept	Literature that describes:	
		How healthcare	
		professionals (including	
		nurses, nurse assistants, and	
		doctors), recognize, assess,	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	
16 17 18 19	
20 21 22	
23 24 25 26 27 28 29 30	238
31 32 33	239
34 35 36	240
37 38	241
39 40 41	242
42 43 44	243
45 46 47	244
48 49	245
50 51 52	246
53 54 55	247
56 57	248 249
58 59 60	250

1

	and evaluate pain in the	
	population	
	Whether and/or how self-	
	reporting of pain is	
	integrated in pain assessment	
	processes in the population	
	How healthcare	
	professionals can support	
	people with dementia in self-	
	reporting of pain	
Study design	All study designs	Editorials, commentaries or letters,
		discussion papers, opinion papers and
	9	nonempirical studies

Study selection will begin with a review of the title and abstract. If these correspond to the
research questions and aim, a full-text review will be conducted. The studies will be reviewed
by at least two researchers; in line with Levac et al., the research team will meet to discuss
study inclusion and exclusion decisions in the beginning, middle, and final stages of the
abstract review process, and refine the search strategy as needed.<sup>33</sup> At least two reviewers will
independently review full-text articles for inclusion; if disagreement arises, an additional
reviewer will be consulted to determine final inclusion.

Levac et al. argue that identifying gaps in the existing literature without assessing the quality
of the included studies may lead to false conclusions about the nature and extent of those
gaps; they also assert that quality assessment of the included studies will increase the
likelihood that findings will be useful for practice.<sup>33</sup> Study quality will be therefore be

Stage 4: Charting data

#### **BMJ** Open

assessed using appropriate appraisal tools, e.g., the Critical Appraisal Skills Programme
(CASP)<sup>37</sup> and Mixed Methods Appraisal Tool (MMAT).<sup>38</sup> An additional researcher will be
included in the decision making if disagreement or uncertainty arise around the quality
assessment.

This stage involves "charting" key items of information obtained from the included studies by sorting material according to relevant issues and themes. In the proposed scoping review, this will be a mixture of general and specific information relating to study design and relevant findings. The charting process is also considered an iterative process, which means that the researchers may continuously update the data-charting form. In line with Levac et al., two researchers will independently extract data from the first five studies using the data-charting form and determine together whether the approach is consistent with the research questions and aim.<sup>33</sup> A preliminary data-charting form has been developed based on Arksey and O'Malley's template (table 3).<sup>32</sup> Ethical mapping is included in the data-charting form, in response to Weingarten et al.'s emphasis on increasing ethical awareness in reviews.<sup>39</sup> Articles that do not adhere to ethical standards will be excluded. 

# 269 Table 3. Data-charting form

• Author, date and country
•
• Study title
• Aim, objective, and/or research questions

2 3	
4 5	
6 7	
8 9	
10 11	
12 13	
14	
15 16	
17 18	270
19 20 21	271
22 23	272
24 25 26	273
27 28	274
29 30 31	275
32 33	276
34 35 36	277
37 38	278
39 40 41	279
42 43	280
44 45 46	281
47 48	282
49 50 51	283
52 53	284
54 55 56	285
57 58	286
59 60	287

1

٠	Ethical assessment (financial support, conflicts of interest,
	informed consent, research committee approval, data
	protection)
٠	Study context
•	Participant characteristics
٠	Sampling method

- Design and methods
- Relevant findings
- 271 Stage 5: Collate, summarize, and report results

272 As Arksey and O'Malley point out, unlike systematic reviews, scoping reviews do not synthesize evidence but instead provide an overview of the reviewed material.<sup>32</sup> In this stage, 273 an overview and summary of the extracted information will therefore be prepared and 274 presented, following the PAGER framework,<sup>40</sup> which consists of five categories: patterns, 275 276 advances, gaps, evidence for practice, and research recommendations. Patterns, or key themes, will be formed by using thematic analysis <sup>41</sup> of key findings from each study included 277 278 in the review. We will then create an overview of advances, gaps, evidence for practice, and research recommendations associated with each pattern.<sup>40</sup> The advances, gaps and research 279 280 recommendations will guide further research needed to develop the pain assessment model, and the evidence for practice will guide the content of the model. Throughout the process, 281 282 there will be regular meetings of the research group to discuss and agree on aspects of the 283 analytical process and how the findings should best be presented.

- 285 Stage 6: Consult with reference group
- <sup>'</sup> 286 This scoping review is the first step in developing a care model for systematic pain
   <sup>3</sup> assessment in people with dementia living in nursing homes, Correspondingly, a reference

# BMJ Open

1 2	
3 4 5	28
5 6 7	28
8 9	29
10 11 12	29
13 14	29
15 16 17	29
17 18 19	29
20 21	29
22 23 24	29
25 26	29 <sup>-</sup>
27 28 29	29
30 31	29
32 33 34	30
35 36	30
37 38 39	30
40 41	30
42 43 44	304
45 46	30
47 48 49	30
50 51	30 <sup>-</sup>
52 53 54	30
55 56	30
57 58 59	20
60	

288	group will be formed, consisting of nursing home residents, relatives, healthcare
289	professionals, and nursing home managers. Arksey and O'Malley recommend consulting with
290	practitioners and consumers to validate findings and make the research more useful for
291	practice. <sup>32</sup> The findings will therefore be presented to and discussed with the reference group.
292	In addition, the research team is part of a larger group of researchers, with whom the findings
293	will also be discussed.
294	
295	Patient and public involvement
296	The proposed scoping review's research questions and aim will be presented to and discussed
297	with the reference group, as will the findings. These latter will support the development of an
298	intervention promoting systematic pain management for people with dementia living in
	mont formen promoting systematic pain management for people with demonstration in the
299	
299	
299 300	
299 300 301	nursing homes.
299 300 301 302	nursing homes. ETHICS AND DISSEMINATION
299 300 301 302 303	nursing homes.  ETHICS AND DISSEMINATION As the scoping review will not involve the collection of primary empirical data, ethical
299 300 301 302 303 304	nursing homes. ETHICS AND DISSEMINATION As the scoping review will not involve the collection of primary empirical data, ethical approval is unecessary. <sup>42</sup> However, following Weingarten et al., <sup>39</sup> who state that ethical
299 300 301 302 303 304 305	nursing homes. <b>ETHICS AND DISSEMINATION</b> As the scoping review will not involve the collection of primary empirical data, ethical approval is unecessary. <sup>42</sup> However, following Weingarten et al., <sup>39</sup> who state that ethical assessments of included studies should be conducted, ethical considerations are included in
299 300 301 302 303 304 305 306	nursing homes. <b>ETHICS AND DISSEMINATION</b> As the scoping review will not involve the collection of primary empirical data, ethical approval is unecessary. <sup>42</sup> However, following Weingarten et al., <sup>39</sup> who state that ethical assessments of included studies should be conducted, ethical considerations are included in the data-charting process. Studies that do not adhere to ethical standards will be excluded.

Page 16 of 29

BMJ Open

2		
3 4 5	310	models or interventions that may be further developed and tailored to the nursing home
6 7	311	context, preventing research waste. <sup>31</sup>
8 9 10	312	
11 12	313	ACKNOWLEDGEMENTS
13 14 15	314	We would like to thank Annelie Ekberg-Andersson and Linda Borg—Information Specialists
16 17	315	at Karlstad University—for their contribution to the search strategy presented in this protocol.
18 19 20	316	
21 22	317	AUTHORS' CONTRIBUTIONS
23 24 25	318	CKO was responsible for the preliminary study design, conceptualized the review approach,
26 27 28	319	and led the writing of this protocol. ML, AH, and SE contributed to the protocol's
29 30	320	development and approved the final version. SE led the supervision of the protocol's
31 32 33	321	preparation.
34 35 36	322	FUNDING STATEMENT
37 38 39	323	This research received no grant from any funding agency in the public, commercial, or not-
40 41 42	324	for-profit sectors.
43 44 45	325	
46 47 48	326	COMPETING INTERESTS STATEMENT
49 50	327	None declared
51 52 53	328	
54	329	
55 56	330	
57 58	331	
58 59 60	332	

1 2		
- 3 4	333	
4 5 6	334	
6 7	001	
8	335	
9 10 11 12 13 14	336	References:
13	337	
15 16 17	338	1. Nichols E, Szoeke CE, Vollset SE, et al. Global, regional, and national burden of
18 19	339	Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the
20 21 22	340	Global Burden of Disease Study 2016. <i>The Lancet Neurology</i> 2019;18(1):88-106.
23 24	341	2. van der Steen JT, Radbruch L, Hertogh CMPM, et al. White paper defining optimal
25 26 27	342	palliative care in older people with dementia: A Delphi study and recommendations
28 29	343	from the European Association for Palliative Care. <i>Palliat Med</i> 2014;28(3):197-209.
30 31 32	344	doi: 10.1177/0269216313493685
33 34	345	3. Houttekier D, Cohen J, Bilsen J, et al. Place of death of older persons with dementia. A
35 36 37	346	study in five European countries. <i>J Am Geriatr Soc</i> 2010;58(4):751-56.
38 39	347	4. Mitchell SL, Teno JM, Miller SC, et al. A national study of the location of death for older
40 41 42	348	persons with dementia. J Am Geriatr Soc 2005;53(2):299-305.
43 44	349	5. Seitz D, Purandare N, Conn D. Prevalence of psychiatric disorders among older adults in
45 46 47	350	long-term care homes: a systematic review. Int Psychogeriatr 2010;22(7):1025-39.
48 49	351	6. Helvik A-S, Engedal K, Benth JŠ, et al. Prevalence and severity of dementia in nursing
50 51 52	352	home residents. Dement Geriatr Cogn Disord 2015;40(3-4):166-77.
53 54	353	7. Hanson E, Hellström A, Sandvide Å, et al. The extended palliative phase of dementia - An
55 56 57	354	integrative literature review. <i>Dementia (London, England)</i> 2019;18(1):108-34. doi:
58 59 60	355	10.1177/1471301216659797 [published Online First: 2016/07/28]

BMJ Open

356	8. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care:
357	2020 report of the Lancet Commission. Lancet 2020;396(10248):413-46. doi:
358	10.1016/s0140-6736(20)30367-6 [published Online First: 2020/08/03]
359	9. Radbruch L, De Lima L, Knaul F, et al. Redefining palliative Care—A new consensus-
360	based definition. J Pain Symptom Manage 2020;60(4):754-64.
361	10. van Dam PH, Caljouw MA, Slettebø DD, et al. Quality of life and pain medication use in
362	persons with advanced dementia living in long-term care facilities. J Am Med Dir
363	Assoc 2019;20(11):1432-37.
364	11. Helvik A-S, Bergh S, Šaltytė Benth J, et al. Pain in nursing home residents with dementia
365	and its association to quality of life. Aging Ment Health 2021:1-11.
366	12. Corbett A, Husebo B, Malcangio M, et al. Assessment and treatment of pain in people
367	with dementia. Nature Reviews Neurology 2012;8(5):264-74.
368	13. Achterberg W, Lautenbacher S, Husebo B, et al. Pain in dementia. Pain reports 2020;5(1)
369	14. Tible OP, Riese F, Savaskan E, et al. Best practice in the management of behavioural and
370	psychological symptoms of dementia. Ther Adv Neurol Disord 2017;10(8):297-309.
371	15. Helsedirektoratet. Nasjonal faglig retningslinje for demens Oslo: Helsedirektoratet; 2017.
372	Updated 03.01.20. Available from:
373	https://www.helsedirektoratet.no/retningslinjer/demens#apiUrl accessed 18.02.22.
374	16. Sirsch E, Lukas A, Drebenstedt C, et al. Guideline workgroup (Schmerzassessment bei
375	älteren Menschen in der vollstationären Altenhilfe, AWMF Registry 145-001). Pain
376	Assessment for Older Persons in Nursing Home Care: An Evidence-Based Practice
377	Guideline. Journal of the American Medical Directors Association 2020;21(2):149-63
	357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 371 372 373 374 375

357	2020 report of the Lancet Commission. Lancet 2020;396(10248):413-46. doi:
358	10.1016/s0140-6736(20)30367-6 [published Online First: 2020/08/03]
359	9. Radbruch L, De Lima L, Knaul F, et al. Redefining palliative Care—A new consensus-
360	based definition. J Pain Symptom Manage 2020;60(4):754-64.
361	10. van Dam PH, Caljouw MA, Slettebø DD, et al. Quality of life and pain medication use in
362	persons with advanced dementia living in long-term care facilities. J Am Med Dir
363	Assoc 2019;20(11):1432-37.
364	11. Helvik A-S, Bergh S, Šaltytė Benth J, et al. Pain in nursing home residents with dementia
365	and its association to quality of life. Aging Ment Health 2021:1-11.
366	12. Corbett A, Husebo B, Malcangio M, et al. Assessment and treatment of pain in people
367	with dementia. Nature Reviews Neurology 2012;8(5):264-74.
368	13. Achterberg W, Lautenbacher S, Husebo B, et al. Pain in dementia. Pain reports 2020;5(1)
369	14. Tible OP, Riese F, Savaskan E, et al. Best practice in the management of behavioural and
370	psychological symptoms of dementia. Ther Adv Neurol Disord 2017;10(8):297-309.
371	15. Helsedirektoratet. Nasjonal faglig retningslinje for demens Oslo: Helsedirektoratet; 2017.
372	Updated 03.01.20. Available from:
373	https://www.helsedirektoratet.no/retningslinjer/demens#apiUrl accessed 18.02.22.
374	16. Sirsch E, Lukas A, Drebenstedt C, et al. Guideline workgroup (Schmerzassessment bei
375	älteren Menschen in der vollstationären Altenhilfe, AWMF Registry 145-001). Pain
376	Assessment for Older Persons in Nursing Home Care: An Evidence-Based Practice
377	Guideline. Journal of the American Medical Directors Association 2020;21(2):149-63.

# BMJ Open

2 3 4	378	17. Woodward M. Aspects of communication in Alzheimer's disease: clinical features and
5 6 7	379	treatment options. Int Psychogeriatr 2013;25(6):877-85.
8 9	380	18. International Associtation for the Study of Pain. Pain terms and definitions 2011.
10 11 12	381	Available from: https://www.iasp-pain.org/resources/terminology/#pain accessed
13 14	382	21.03 2022.
15 16 17	383	19. Dodd M, Janson S, Facione N, et al. Advancing the science of symptom management. J
18 19	384	Adv Nurs 2001;33(5):668-76.
20 21 22	385	20. Lenz ER, Pugh LC, Milligan RA, et al. The Middle-Range Theory of Unpleasant
23 24	386	Symptoms: An Update. Advances in Nursing Science 1997;19(3):14-27.
25 26 27	387	21. Ellis-Smith C, Evans CJ, Bone AE, et al. Measures to assess commonly experienced
28 29	388	symptoms for people with dementia in long-term care settings: a systematic review.
30 31 32	389	<i>BMC medicine</i> 2016;14(1):1-12.
33 34	390	22. Husebo B, Ostelo R, Strand LI. The MOBID-2 pain scale: Reliability and responsiveness
35 36 37	391	to pain in patients with dementia. <i>European journal of pain</i> 2014;18(10):1419-30.
38 39	392	23. Torvik K, Kaasa S, Kirkevold Ø, et al. Validation of Doloplus-2 among nonverbal nursing
40 41 42	393	home patients-an evaluation of Doloplus-2 in a clinical setting. BMC Geriatr
43 44 45	394	2010;10(1):1-9.
45 46 47	395	24. Dowding D, Lichtner V, Allcock N, et al. Using sense-making theory to aid understanding
48 49 50	396	of the recognition, assessment and management of pain in patients with dementia in
50 51 52	397	acute hospital settings. Int J Nurs Stud 2016;53:152-62.
53 54	398	25. Pautex S, Michon A, Guedira M, et al. Pain in severe dementia: Self-assessment or
55 56 57 58 59 60	399	observational scales? <i>J Am Geriatr Soc</i> 2006;54(7):1040-45.

Page 20 of 29

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

# BMJ Open


2		
3 4 5	400	26. De Witt Jansen B, Brazil K, Passmore P, et al. Exploring healthcare assistants' role and
6 7	401	experience in pain assessment and management for people with advanced dementia
8 9	402	towards the end of life: a qualitative study. BMC Palliat Care 2017;16(1):1-11.
10 11 12	403	27. De Witt Jansen B, Brazil K, Passmore P, et al. Nurses' experiences of pain management
13 14	404	for people with advanced dementia approaching the end of life: a qualitative study.
15 16 17	405	Journal of Clinical Nursing (John Wiley & Sons, Inc) 2017;26(9-10):1234-44. doi:
18 19	406	10.1111/jocn.13442
20 21 22	407	28. De Witt Jansen B, Brazil K, Passmore P, et al. "A tool doesn't add anything". The
23 24	408	importance of added value: Use of observational pain tools with patients with
25 26 27	409	advanced dementia approaching the end of life-a qualitative study of physician and
28 29	410	nurse experiences and perspectives. International Journal of Geriatric Psychiatry
30 31 32	411	2018;33(7). doi: 10.1002/gps.4931
33 34	412	29. Monroe TB, Parish A, Mion LC. Decision Factors Nurses Use to Assess Pain in Nursing
35 36 37	413	Home Residents With Dementia. Archives of Psychiatric Nursing 2015;29(5):316-20.
38 39	414	doi: 10.1016/j.apnu.2015.05.007
40 41	415	30. Skivington K, Matthews L, Simpson SA, et al. Framework for the development and
42 43		
44 45	416	evaluation of complex interventions: gap analysis, workshop and consultation-
46 47	417	informed update. Health Technol Assess 2021
48 49 50	418	31. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research
50 51 52	419	evidence. The Lancet 2009;374(9683):86-89.
53 54	420	32. Arksey H, O'Malley L. Scoping studies: towards a methodological framework.
55 56 57 58 59	421	International journal of social research methodology 2005;8(1):19-32.
60		


# BMJ Open

2 3	422	33. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology.
4 5	422	55. Levac D, Colquilouli H, O Briell KK. Scoping studies. advancing the methodology.
6 7	423	Implementation science 2010;5(1):1-9.
8 9 10	424	34. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review
10 11 12	425	and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews
13 14 15	426	2015;4(1):1-9.
15 16 17	427	35. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-
18 19	428	ScR): checklist and explanation. Ann Intern Med 2018;169(7):467-73.
20 21 22	429	36. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated
23 24	430	guideline for reporting systematic reviews. International Journal of Surgery
25 26 27	431	2021;88:105906.
28 29 30 31 32 33 34 35	432	37. CASP Checklist: CASP Critical appraisal skills programme 2018 [Available from:
	433	https://casp-uk.b-cdn.net/wp-content/uploads/2018/01/CASP-Qualitative-Checklist-
	434	2018.pdf accessed 25.08.21.
36 37	435	38. Hong QN, Fàbregues S, Bartlett G, et al. The Mixed Methods Appraisal Tool (MMAT)
38 39 40	436	version 2018 for information professionals and researchers. Education for Information
41 42	437	2018;34(4):285-91.
43 44 45	438	39. Weingarten MA, Paul M, Leibovici L. Assessing ethics of trials in systematic reviews.
46 47	439	BMJ2004;328(7446):1013-14.
48 49 50	440	40. Bradbury-Jones C, Aveyard H, Herber OR, et al. Scoping reviews: the PAGER
51 52	441	framework for improving the quality of reporting. International Journal of Social
53 54 55	442	Research Methodology 2021:1-14.
56 57	443	41. Braun V, Clarke V, Braun V. Thematic analysis : a practical guide. Los Angeles,
58 59 60	444	California: SAGE 2022.

BMJ Open

445	42. Helseforskningsloven. Lov om medisinsk og helsefaglig forskning: Helse- og
116	omsorgsdepartementet, 2008.
440	omsorgsuepartementet, 2008.
447	
	Figure legends:
450	
451	Figure 1: Overview study selection process using PRISMA Flow Diagram. <sup>36</sup>
	446 447 448 449 450





\*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).

\*\*If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

# PRISMA-P 2015 Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* **2015** 4:1

Section/topic	#	Checklist item	Informat reported		Line number(s)		
			Yes	No			
ADMINISTRATIVE INFORMATION							
Title							
Identification	1a	Identify the report as a protocol of a systematic review			5-6		
Update	1b	If the protocol is for an update of a previous systematic review, identify as such		$\square$			
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract			67		
Authors		4					
Contact	3а	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author			12-25		
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review			357-361		
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments					
Support		*			-		
Sources	5а	Indicate sources of financial or other support for the review			362-364		
Sponsor	5b	Provide name for the review funder and/or sponsor		$\square$			
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol		$\square$			
INTRODUCTION							
Rationale	6	Describe the rationale for the review in the context of what is already known			130-197		
Objectives	7	Provide an explicit statement of the question(s) the review will address with			222-229		

Section/topic	#	Checklist item	Information reported		Line
			Yes	No	number(s)
		reference to participants, interventions, comparators, and outcomes (PICO)			
METHODS					
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review			272-273
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage			239-240
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated			244-247 Supplementar file 3
STUDY RECORDS					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review			259-262
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)			254-290
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators			292-303
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications			305-306
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale			
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis			

Section/topic	#	Checklist item	Informa reporte		Line	
• • • • • • •			Yes	No		
	15a	Describe criteria under which study data will be quantitatively synthesized				
Synthesis	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., <i>I</i> <sup>2</sup> , Kendall's tau)				
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)				
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned			308-320	
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)				
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)				

# **SUPPLEMENTARY FILE 2**

# Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			UNTAGE #
Title	1	Identify the report as a scoping review.	1
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	4-5
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	6
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	1
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	7-8
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	6-7
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Supplementary file 3
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	7-8
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	9
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	9
Critical appraisal of individual	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this	9

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
sources of evidence§		information was used in any data synthesis (if appropriate).	
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	9
RESULTS			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	Click here to enter text.
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	Click here to enter text.
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Click here to enter text.
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	Click here to enter text.
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	Click here to enter text.
DISCUSSION	1		
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	Click here to enter text.
Limitations	20	Discuss the limitations of the scoping review process.	Click here to enter text.
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	Click here to enter text.
FUNDING			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	11

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

\* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).
‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to

the process of data extraction in a scoping review as data charting. § The process of systematically examining research evidence to assess its validity, results, and relevance before

using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMAScR): Checklist and Explanation. Ann Intern Med. 2018;169:467–473. doi: 10.7326/M18-0850.

#### **SUPPLEMENTARY FILE 3**

#### MEDLINE, Search conducted 11.02.22

#### Database:

Ovid MEDLINE(R) ALL <1946 to February 10, 2022>

#	Query	Results from 11 Feb 2022	
1	dementia/ or alzheimer disease/ or dementia, vascular/ or frontotemporal lobar degeneration/ or lewy body disease/	160,450	
	Frontotemporal Dementia/ or Dementia, Multi-Infarct/	4,719	
3	Korsakoff Syndrome/	530	
4	Dementia.ab,ti.	121,195	
5	"Alzheimer*".ab,ti.	163,697	
6	Lewy body.ab,ti.	4,218	
7	korsakoff.ab,ti.	985	
8	1 or 2 or 3 or 4 or 5 or 6 or 7	265,108	
	exp Pain/ or exp Pain Measurement/ or exp Pain Management/	471,353	
	Pain.ab,ti.	694,136	
11	9 or 10	872,991	
12	"Care home*".af.	5,045 🥒	
13	Long term care.af.	46,819	
14	Residential care.af.	4,053	
15	"nurs* home*".af.	52,581	
16	exp Residential Facilities/ or exp Nursing Homes/ or exp Homes for the Aged/ or exp Long-Term Care/	77,440	
17	"Home* for the aged".af.	15,709	
18	12 or 13 or 14 or 15 or 16 or 17	107,035	
19	8 and 11 and 18	750	